MAYO CLINIC LABORATORIES

BCR/ABL1 ORDERING GUIDE FOR BLOOD AND BONE MARROW*

*Extracted RNA is not an acceptable specimen and will be rejected if received.

	TEST ID	TEST NAME	APPROPRIATE ORDERING SCENARIO
DIAGNOSIS	BCRFX	*BCR/ABL1*, Reflex, Qual/Quant	Qualitative with reflex to Quantitative. Detects common transcript fusions (p210, p190) and other rare fusions. If p210 or p190 fusion form is specifically identified, quantitative testing is performed to provide initial transcript level. Should NOT be used in patients with a previously established diagnosis of *BCR-ABL1* p210 or p190 positive disease requiring monitoring on therapy. In this case use specific quantitative PCR tests (Test IDs: BCRAB or BA190) as appropriate.
	BADX	*BCR/ABL1* RNA-Qual, Diagnostic	Qualitative only. Useful screening assay for presence of *BCR-ABL1* disease and for identifying the *BCR-ABL1* transcript fusion form at time of diagnosis. Detects common transcript fusions (p210, p190) and can also be used for qualitative monitoring of rare fusion types (i.e. fusions that are not p210 or p190). Will NOT provide a quantitative value.
FOLLOW-UP (QUANTITATIVE)		ORDER BASED ON RESULTS OBTAINED FROM DIAGNOSTIC TESTING	
	BCRAB	*BCR/ABL1*, p210, Quant, Monitor	Quantitative assay for monitoring p210 fusion form only. Will not detect other *BCR-ABL1* fusion types, including the p190.
	BA190	*BCR/ABL1*, p190, Quant, Monitor	Quantitative assay for monitoring p190 fusion form only. Will not detect other *BCR-ABL1* fusion types, including the p210.
ADDITIONAL TESTING	BAKDM	*BCR/ABL1* Mutation, Sequencing	To identify the presence of acquired *BCR-ABL1* mutations associated with resistance to tyrosine kinase inhibitor (TKI) therapy. Testing should be considered when quantitative *BCR-ABL1* levels are increasing by 0.5 log or more in consecutive samples, or therapy is not achieving expected response.